Combined therapy for diabetic macular edema.

Diabetic macular edema (DME) is the main cause of visual impairment in diabetic patients. Macular edema within 1 disk diameter of the fovea is present...
1MB Sizes 1 Downloads 0 Views

Recommend Documents

Anti-VEGF therapy for diabetic macular edema.
Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of diabetic macular edema (DME), the leading cause of vision loss among working-aged individuals. A decade of clinical trials demonstrated that drugs that bind soluble

Ascorbic acid repletion: A possible therapy for diabetic macular edema?
Macular edema poses a significant risk for visual loss in persons with diabetic retinopathy. It occurs when plasma constituents and fluid leak out of damaged retinal microvasculature in the area of the macula, causing loss of central vision. Apoptoti

Diabetic macular edema.
Diabetic macular edema (DME) is one of the most common causes of visual loss in patients with diabetes mellitus. Many patients continue to lose vision despite laser photocoagulation and medical therapies. The two major categories of medications curre

Diabetic Macular Edema.
Diabetic macular edema (DME), one the most prevalent causes of visual loss in industrialized countries, may be diagnosed at any stage of diabetic retinopathy. The diagnosis, treatment, and follow up of DME have become straightforward with recent deve

Emerging drugs for diabetic macular edema.
Diabetic macular edema (DME) is the most common cause of visual impairment due to diabetic retinopathy. The treatment of DME has recently undergone a paradigm shift. Traditionally, photocoagulation was standard treatment, but pharmacologic therapies

Vitrectomy for center-involved diabetic macular edema.
To determine the effect of vitrectomy for center-involved diabetic macular edema (CI-DME).

Intravitreal aflibercept for diabetic macular edema.
A head-to-head comparison was performed between vascular endothelial growth factor blockade and laser for treatment of diabetic macular edema (DME).

Update on corticosteroids for diabetic macular edema.
Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for

Diabetic Retinopathy and Diabetic Macular Edema.
Diabetic retinopathy and diabetic macular edema result from chronic damage to the neurovascular structures of the retina. The pathophysiology of retinal damage remains uncertain but includes metabolic and neuroinflammatory insults. These mechanisms a

Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study.
To compare the efficacy of different therapies in the treatment of diabetic macular edema (DME).